No Data
Is The Market Rewarding Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Chinese Drug Regulator Accepts Salubris Pharmaceuticals' Application to Trial Hypertension Drug
Huayoung Asia Vets (301502.SZ): The main clients of the injection pen Business include well-known biopharmaceutical companies such as Jinsai Pharmaceuticals, Haosen Pharmaceuticals, and Shenzhen Salubris Pharmaceuticals.
On February 13, Gelonghui reported that Huayang Intelligent (301502.SZ) stated during an investor relations activity that the company's precision drug delivery devices are primarily divided into electronic and Machinery injection pens. The electronic injection pen is the company's core product, which also includes a series of Machinery injection pen products. The company is one of the early starters in domestic injection pen production with a relatively complete product line, and its main clients include well-known biopharmaceutical companies such as Jin Sai Pharmaceutical, Hao Sen Pharmaceutical, and Shenzhen Salubris Pharmaceuticals. The future market space for injections is vast. There is great growth potential for diabetes medications, weight loss drugs, etc., and the domestic penetration rate for growth hormones and osteoporosis medications is still very low, along with Other medications such as follicle-stimulating hormones and monoclonal antibodies.
Shenzhen Salubris Pharmaceuticals (002294.SZ): The clinical trial application for SAL0140 pharmaceutical has been accepted.
On February 13, Glonghui reported that Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that recently, the company received a notification from the National Medical Products Administration approving the acceptance of the application. The company's independently developed innovative small molecule drug SAL0140 tablets (project code: SAL0140) has received acceptance for clinical trial application. The application submitted by the company is for clinical trials of SAL0140 for the treatment of uncontrolled hypertension (including resistant hypertension). Preclinical studies show that SAL0140 selectively inhibits the activity of aldosterone synthase, achieving suppression of aldosterone synthesis without affecting.
Orient: The market prospects for lipid-lowering drugs are broad, with new targets and new technological routes continually being validated.
Due to the rising incidence of dyslipidemia, which is increasingly affecting younger populations, the market for lipid-lowering drugs has a broad outlook. At the same time, new targets and new technological routes are being continuously validated, and the approval of Innovative Drugs can also drive rapid market expansion.
Shenzhen Salubris Pharmaceuticals (002294.SZ): JK07 obtained positive interim data in the MRCT II phase clinical trials for patients with HFrEF and HFpEF.
On January 20, Galunhui reported that Shenzhen Salubris Pharmaceuticals (002294.SZ) announced that it recently received a notification from its subsidiary, Salubris Biotherapeutics, Inc. in the USA, that JK07 has obtained positive interim data in the MRCT II phase clinical trial for patients with HFrEF (Heart Failure with Reduced Ejection Fraction) and HFpEF (Heart Failure with Preserved Ejection Fraction). The interim analysis of the phase II clinical study of JK07 aims to evaluate JK07 in the low-dose group (0.045.